Literature DB >> 10412777

Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy.

T Nakao1, M Yoshino, H Matsumoto, T Okada, M Han, H Hidaka, T Shino, C Yamada, Y Nagaoka, T Miyahara.   

Abstract

BACKGROUND: Hyperlipidemia has recently received attention as being involved in the progression of diabetic nephropathy (DN). Low-density lipoprotein apheresis (LDL-A) can remove a large amount of plasma lipid directly from the patients in a short time.
METHODS: Fifteen type 2 diabetic patients with overt nephropathy received LDL-A in two different manners: short-term intensive therapy (SIT) for nine patients and long-term intermittent therapy (LIT) for six patients.
RESULTS: The changes in the monthly decline rates of reciprocal serum creatinine (1/Cr) were -0.035 +/- 0.020 in the three-month period before SIT, 0.047 +/- 0.041 during and until two weeks after SIT, and -0.035 +/- 0.015 after a period of two weeks from the therapy. The mean duration of LIT in six patients was 8.2 +/- 7.4 months, and the mean monthly decline rates of 1/Cr significantly decreased during the period of LIT as compared with the six-month period before the treatment.
CONCLUSION: LDL-A can retard the progression of overt DN, especially when it is performed repeatedly for a long period at two-week intervals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412777     DOI: 10.1046/j.1523-1755.1999.07153.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  5 in total

1.  Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia.

Authors:  Takashi Wada; Eri Muso; Shoichi Maruyama; Akinori Hara; Kengo Furuichi; Kenichi Yoshimura; Mariko Miyazaki; Eiichi Sato; Masanori Abe; Yugo Shibagaki; Ichiei Narita; Hitoshi Yokoyama; Noriko Mori; Yukio Yuzawa; Takeshi Matsubara; Tatsuo Tsukamoto; Jun Wada; Takafumi Ito; Kosuke Masutani; Kazuhiko Tsuruya; Shoichi Fujimoto; Akihiro Tsuda; Hitoshi Suzuki; Kenji Kasuno; Yoshio Terada; Takeshi Nakata; Noriaki Iino; Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2017-10-27       Impact factor: 2.801

Review 2.  Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses.

Authors:  P M Moriarty; C A Gibson
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

Review 3.  Applications of LDL-apheresis in nephrology.

Authors:  Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

4.  Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis.

Authors:  Junko Yabuuchi; Tatsuya Suwabe; Hiroki Mizuno; Toshiharu Ueno; Junichi Hoshino; Akinari Sekine; Masahiro Kawada; Masayuki Yamanouchi; Noriko Hayami; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi; Takeshi Fujii; Kenichi Ohashi; Yoshifumi Ubara
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

5.  A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Tsukasa Takemura; Yukio Yuzawa; Satoru Ogahara; Satoshi Sugiyama; Yasuhiko Iino; Soichi Sakai; Yousuke Ogura; Susumu Yukawa; Yoshiki Nishizawa; Noriaki Yorioka; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Nephron Extra       Date:  2015-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.